Valion Bio Statistics
Total Valuation
Valion Bio has a market cap or net worth of $2.39 million. The enterprise value is $12.20 million.
| Market Cap | 2.39M |
| Enterprise Value | 12.20M |
Important Dates
The last earnings date was Thursday, May 14, 2026, after market close.
| Earnings Date | May 14, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Valion Bio has 3.14 million shares outstanding. The number of shares has increased by 324.89% in one year.
| Current Share Class | 3.14M |
| Shares Outstanding | 3.14M |
| Shares Change (YoY) | +324.89% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 2.35% |
| Owned by Institutions (%) | 15.06% |
| Float | 3.00M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.20 |
| P/TBV Ratio | 0.44 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.31, with a Debt / Equity ratio of 1.54.
| Current Ratio | 3.31 |
| Quick Ratio | 2.76 |
| Debt / Equity | 1.54 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -15.31 |
Financial Efficiency
Return on equity (ROE) is -182.22% and return on invested capital (ROIC) is -48.80%.
| Return on Equity (ROE) | -182.22% |
| Return on Assets (ROA) | -36.18% |
| Return on Invested Capital (ROIC) | -48.80% |
| Return on Capital Employed (ROCE) | -34.14% |
| Weighted Average Cost of Capital (WACC) | 4.96% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$261,115 |
| Employee Count | 52 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -81.69% in the last 52 weeks. The beta is 1.79, so Valion Bio's price volatility has been higher than the market average.
| Beta (5Y) | 1.79 |
| 52-Week Price Change | -81.69% |
| 50-Day Moving Average | 0.96 |
| 200-Day Moving Average | 1.71 |
| Relative Strength Index (RSI) | 42.36 |
| Average Volume (20 Days) | 118,349 |
Short Selling Information
The latest short interest is 203,277, so 6.48% of the outstanding shares have been sold short.
| Short Interest | 203,277 |
| Short Previous Month | 245,772 |
| Short % of Shares Out | 6.48% |
| Short % of Float | 6.77% |
| Short Ratio (days to cover) | 1.26 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -12.16M |
| Pretax Income | -12.85M |
| Net Income | -13.58M |
| EBITDA | -12.15M |
| EBIT | -12.16M |
| Earnings Per Share (EPS) | -$7.91 |
Balance Sheet
The company has $7.22 million in cash and $17.03 million in debt, with a net cash position of -$9.82 million or -$3.13 per share.
| Cash & Cash Equivalents | 7.22M |
| Total Debt | 17.03M |
| Net Cash | -9.82M |
| Net Cash Per Share | -$3.13 |
| Equity (Book Value) | 11.06M |
| Book Value Per Share | 3.84 |
| Working Capital | 6.04M |
Cash Flow
In the last 12 months, operating cash flow was -$11.12 million and capital expenditures -$45,000, giving a free cash flow of -$11.17 million.
| Operating Cash Flow | -11.12M |
| Capital Expenditures | -45,000 |
| Depreciation & Amortization | 8,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -11.17M |
| FCF Per Share | -$3.56 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Valion Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -324.89% |
| Shareholder Yield | -324.89% |
| Earnings Yield | -569.14% |
| FCF Yield | -468.04% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on March 7, 2025. It was a reverse split with a ratio of 1:17.
| Last Split Date | Mar 7, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:17 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |